<VariationArchive VariationID="1776474" VariationName="NM_144997.7(FLCN):c.1615dup (p.Leu539fs)" VariationType="Duplication" Accession="VCV001776474" Version="3" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-10" DateCreated="2022-11-29" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1837704" VariationID="1776474">
      <GeneList>
        <Gene Symbol="FLCN" FullName="folliculin" GeneID="201163" HGNC_ID="HGNC:27310" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p11.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="17212212" stop="17237330" display_start="17212212" display_stop="17237330" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="17115525" stop="17140501" display_start="17115525" display_stop="17140501" Strand="-" />
          </Location>
          <OMIM>607273</OMIM>
          <Haploinsufficiency last_evaluated="2023-01-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FLCN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2023-01-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FLCN">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_144997.7(FLCN):c.1615dup (p.Leu539fs)</Name>
      <CanonicalSPDI>NC_000017.11:17213779:GG:GGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>17p11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="17213779" stop="17213780" display_start="17213779" display_stop="17213780" variantLength="1" positionVCF="17213779" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="17117093" stop="17117094" display_start="17117093" display_stop="17117094" variantLength="1" positionVCF="17117093" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
      </Location>
      <ProteinChange>L557fs</ProteinChange>
      <ProteinChange>L539fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.17117095dup" Assembly="GRCh37">
            <Expression>NC_000017.10:g.17117095dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.17213781dup" Assembly="GRCh38">
            <Expression>NC_000017.11:g.17213781dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008001.2" sequenceAccession="NG_008001" sequenceVersion="2" change="g.28409dup">
            <Expression>NG_008001.2:g.28409dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001353229.2" sequenceAccession="NM_001353229" sequenceVersion="2" change="c.1669dup">
            <Expression>NM_001353229.2:c.1669dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001340158.1" sequenceAccession="NP_001340158" sequenceVersion="1" change="p.Leu557fs">
            <Expression>NP_001340158.1:p.Leu557fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001353230.2" sequenceAccession="NM_001353230" sequenceVersion="2" change="c.1615dup">
            <Expression>NM_001353230.2:c.1615dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001340159.1" sequenceAccession="NP_001340159" sequenceVersion="1" change="p.Leu539fs">
            <Expression>NP_001340159.1:p.Leu539fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001353231.2" sequenceAccession="NM_001353231" sequenceVersion="2" change="c.1615dup">
            <Expression>NM_001353231.2:c.1615dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001340160.1" sequenceAccession="NP_001340160" sequenceVersion="1" change="p.Leu539fs">
            <Expression>NP_001340160.1:p.Leu539fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_144997.7" sequenceAccession="NM_144997" sequenceVersion="7" change="c.1615dup" MANESelect="true">
            <Expression>NM_144997.7:c.1615dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_659434.2" sequenceAccession="NP_659434" sequenceVersion="2" change="p.Leu539fs">
            <Expression>NP_659434.2:p.Leu539fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_144997.5" sequenceAccession="NM_144997" sequenceVersion="5" change="c.1615dupC">
            <Expression>NM_144997.5:c.1615dupC</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_325" sequenceAccession="LRG_325">
            <Expression>LRG_325:g.28409dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_325t1" sequenceAccession="LRG_325t1">
            <Expression>LRG_325t1:c.1614dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_325p1" sequenceAccession="LRG_325p1" change="p.Leu539Profs">
            <Expression>LRG_325p1:p.Leu539Profs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_144997.7(FLCN):c.1615dup (p.Leu539fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV002400963" Version="2">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-01-12" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_144997.7(FLCN):c.1615dup (p.Leu539fs) AND Birt-Hogg-Dube syndrome" Accession="RCV003607522" Version="1">
        <ClassifiedConditionList TraitSetID="860">
          <ClassifiedCondition DB="MedGen" ID="C0346010">Birt-Hogg-Dube syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-02-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-02-28" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2022-11-29" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">28558743</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-17">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="860" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1028" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Birt-Hogg-Dube syndrome</ElementValue>
                <XRef ID="MONDO:0800444" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">BHD syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Birt Hogg Dub√© syndrome</ElementValue>
                <XRef ID="1263460007" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BHD</ElementValue>
                <XRef Type="MIM" ID="135150" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The clinical characteristics of Birt-Hogg-Dub√© syndrome (BHDS) include cutaneous manifestations (fibrofolliculomas, acrochordons, angiofibromas, oral papules, cutaneous collagenomas, and epidermal cysts), pulmonary cysts/history of pneumothorax, and various types of renal tumors. Disease severity can vary significantly even within the same family. Skin lesions typically appear between the second and fourth decades of life and typically increase in size and number with age. Lung cysts are often bilateral and multifocal; most individuals are asymptomatic but at high risk for spontaneous pneumothorax. Individuals with BHDS are at a sevenfold increased risk for renal tumors that can be bilateral and multifocal; median age of renal tumor diagnosis is 48 years. The most common renal tumors are a hybrid of oncocytoma and chromophobe histologic cell types (oncocytic hybrid tumor) and chromophobe histologic cell types. Some families have renal tumor(s) and/or spontaneous pneumothorax without cutaneous manifestations.</Attribute>
                <XRef ID="NBK1522" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2322" />
                <XRef ID="2322" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301695</ID>
                <ID Source="BookShelf">NBK1522</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Birt-Hogg-Dub√© syndrome">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/bhd-syndrome</URL>
                <CitationText>PDQ¬Æ Cancer Genetics Editorial Board. PDQ Birt-Hogg-Dub√© Syndrome. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="122" DB="Orphanet" />
              <XRef ID="C0346010" DB="MedGen" />
              <XRef ID="MONDO:0800444" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS135150" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8158579" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="14530882|MedGen:C0346010" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004370158" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">28558743</ID>
          </Citation>
          <Comment>This sequence change results in a frameshift in the FLCN gene (p.Leu539Profs*63). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 41 amino acid(s) of the FLCN protein and extend the protein by 21 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FLCN-related conditions. ClinVar contains an entry for this variant (Variation ID: 1776474). This variant disrupts a region of the FLCN protein in which other variant(s) (p.Trp553*) have been determined to be pathogenic (PMID: 28558743; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FLCN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.17117093_17117094insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0346010" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5193000" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a186454|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002705274" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-01-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The c.1615dupC variant, located in coding exon 11 of the FLCN gene, results from a duplication of C at nucleotide position 1615, causing a translational frameshift with a predicted alternate stop codon (p.L539Pfs*63). This frameshift occurs at the 3' end of FLCN, is not expected to trigger nonsense-mediated mRNA decay, impacts only the last 7%/41 amino acids of the protein, and elongates the FLCN protein by 21 amino acids. Frameshifts are typically deleterious in nature and there are multiple similar alterations classified as pathogenic including FLCN c. 1597_1598delCA (p.Q533Efs*68) and FLCN c.1579_1580insA (p.R527Qfs*75) (Ambry Internal Data; Furuya M et al. Am J Surg Pathol, 2012 Apr;36:589-600; Yang CY et al. J Postgrad Med;59:321-3; Liu L et al. Biomed Res Int, 2017 Jul;2017:8751384; Hou X et al. BMC Med Genet, 2018 01;19:14). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FLCN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_144997.5:c.1615dupC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5193000" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8158579" TraitType="Disease" MappingType="XRef" MappingValue="C0346010" MappingRef="MedGen">
        <MedGen CUI="C0346010" Name="Birt-Hogg-Dube syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

